Hartford Alpha Capture Growth ETF (ACGO)

On our risk desk, we are closely tracking ACGO's portfolio risk score of 85, which places it squarely in the 'very aggressive' bracket. Combined with its non-diversified status, we are advising clients to account for concentrated sector exposure, especially given its heavy reliance on Wellington's bottom-up stock picking across healthcare and tech.

When analyzing ACGO's initial performance metrics, our quant group noted that bottom-up stock selection was the primary driver of relative outperformance against the Russell 1000 Growth Index. The strategy's overweight exposure to healthcare successfully offset the drag from industrial and consumer staple underweights during the recent quarter.

Watching the market sentiment roll in on ACGO since its June 2, 2026 launch, the narrative centers heavily on Wellington's fundamental equity pedigree. Institutional players appreciate the multi-team alpha capture model, though macroeconomic fears regarding US-Iran conflicts and inflation are tempering aggressive equity inflows.

Reviewing the fund's structural mechanics, ACGO utilizes a disciplined portfolio construction framework designed to limit unintended risks while prioritizing high-potential stock ideas. With Thomas S. Simon at the helm backed by Wellington's 300+ equity professionals, the execution relies entirely on internal idea mapping across diverse alpha sources.

As a bio-analyst looking at broader market sector rotations, I'm intrigued by ACGO's deliberate healthcare overweighting. Since the fund relies on high-conviction ideas from multiple Wellington teams, its ability to capitalize on fundamental biotech and healthcare catalysts will be the ultimate test of its alpha-generation thesis.